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UnBACKGROUND Hemodialysis patients are high absorbers of intestinal cholesterol; they beneﬁt less than other patient
groups from statin therapy, which inhibits cholesterol synthesis.
OBJECTIVES This study sought to investigate whether the individual cholesterol absorption rate affects atorvastatin’s
effectiveness to reduce cardiovascular risk in hemodialysis patients.
METHODS This post-hoc analysis included 1,030 participants in the German Diabetes and Dialysis Study (4D) who were
randomized to either 20 mg of atorvastatin (n ¼ 519) or placebo (n ¼ 511). The primary endpoint was a composite of
major cardiovascular events. Secondary endpoints included all-cause mortality and all cardiac events. Tertiles of the
cholestanol-to-cholesterol ratio, which is an established biomarker of cholesterol absorption, were used to identify high
and low cholesterol absorbers.
RESULTS A total of 454 primary endpoints occurred. On multivariate time-to-event analyses, the interaction term
between tertiles and treatment with atorvastatin was signiﬁcantly associated with the risk of reaching the primary
endpoint. Stratiﬁed analysis by cholestanol-to-cholesterol ratio tertiles conﬁrmed this effect modiﬁcation: atorvastatin
reduced the risk of reaching the primary endpoint in the ﬁrst tertile (hazard ratio [HR]: 0.72; p ¼ 0.049), but not the
second (HR: 0.79; p ¼ 0.225) or third tertiles (HR: 1.21; p ¼ 0.287). Atorvastatin consistently signiﬁcantly reduced all-
cause mortality and the risk of all cardiac events in only the ﬁrst tertile.
CONCLUSIONS Intestinal cholesterol absorption, as reﬂected by cholestanol-to-cholesterol ratios, predicts the
effectiveness of atorvastatin to reduce cardiovascular risk in hemodialysis patients. Those with low cholesterol absorp-
tion appear to beneﬁt from treatment with atorvastatin, whereas those with high absorption do not beneﬁt.
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2292(5–8). Speciﬁcally, 20 mg of atorvastatin
versus placebo did not signiﬁcantly reduce
the composite risk of CV death, nonfatal
myocardial infarction (MI), and stroke in
the 4D (German Diabetes Dialysis Study)
study (7). Likewise, 10 mg of rosuvastatin
did not signiﬁcantly reduce the composite
risk of death from CV causes, nonfatal MI,and nonfatal stroke in the AURORA (A Study to Eval-
uate the Use of Rosuvastatin in Subjects on Regular
Hemodialysis: An Assessment of Survival and Cardio-
vascular Events) study (8). The reasons for these
results remain incompletely understood (9).SEE PAGE 2299Body cholesterol, which comes from 2 sources, is
either endogenously synthesized or taken up from the
diet in the intestine (10). Statins inhibit cholesterol
synthesis, but they do not interfere with cholesterol
absorption (10). Notably, patients on maintenance
hemodialysis treatment are high absorbers of intesti-
nal cholesterol, which may account for the low effec-
tiveness of atorvastatin to reduce CV risk in these
patients (11). The present research was therefore
stimulated by the question as to whether the individ-
ual cholesterol absorption rate may modify the effec-
tiveness of atorvastatin treatment to reduce CV risk
in hemodialysis patients.
To answer this question, we performed a post-hoc
analysis of data from the 4D study (7). Cholesterol
absorption efﬁciency was estimated using an estab-
lished biomarker, namely, the circulating cholestanol-
to-total cholesterol ratio (12,13).
METHODS
STUDY DESIGN AND PARTICIPANTS. The design of
4D has been previously reported (7,14). Brieﬂy, 4D is a
prospective, randomized, double-blind, multicenter
trial that included 1,255 patients with type 2 diabetes,
who were 18 to 80 years of age, and who were on
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ticipants of the 4D study. Among the 1,030 partici-
pants with available data on cholestanol, 519 patients
received 20 mg of atorvastatin and 511 patients
received placebo once daily. They were re-examined
at 4 weeks and then every 6 months after randomi-
zation to obtain information about study endpoints or
serious adverse events. The study was approved by
the local medical ethics committee, and written
informed consent was obtained from all participants
before inclusion. The data were monitored and
collected by a contract research organization (7).
ENDPOINTS. The study endpoints and serious
adverse events were reported to the contract research
organization. Every endpoint was adjudicated by 3
members of the endpoint committee on the basis of
pre-deﬁned criteria that were part of the study pro-
tocol. The classiﬁcation by the endpoint committee
was on the basis of consensus or majority vote. All
committee members were blinded to the treatment
assignments until August 13, 2004 (7). The primary
endpoint of the 4D study was a composite of death
resulting from cardiac causes, fatal or nonfatal stroke,
and nonfatal MI. Death resulting from cardiac causes
included sudden death, fatal MI, death caused by
congestive heart failure, death resulting from coro-
nary heart disease (CHD) during or within 28 days
after an intervention, and all other deaths ascribed
to CHD. Sudden cardiac death was considered death
as veriﬁed by terminal rhythm disorders as seen on
an electrocardiogram (ECG), witness-observed death
within 1 hour after the onset of cardiac symptoms,
death conﬁrmed by autopsy, and unexpected death of
presumably or possibly of cardiac origin and in the
absence of an increased potassium level before the
start of the 3 most recent hemodialysis treatment
sessions. MI was diagnosed when 2 of the following 3
criteria were met: typical symptoms; elevated levels
of cardiac enzymes (creatine kinase-MB, lactic dehy-
drogenase, and troponin T); or diagnostic changes on
the ECG. An ECG at rest was recorded every 6 monthssearch, Palaiseau, France. Dr. Wanner received grant
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2293and evaluated by independent cardiologists from the
ECG monitoring board, according to the Minnesota
classiﬁcation system for ECGs (codes 1-1-1 through 9-2
for QRS complex, ST-segment, or T-wave changes).
An ECG that documented silent MI was considered
evidence of a primary endpoint. When death occurred
within 28 days post-MI, as previously described,
it was classiﬁed as death caused by MI. Fatal MI was
classiﬁed only as death from MI, not sudden cardiac
death. “All cardiac events” were deﬁned as a com-
posite of cardiac death, nonfatal MI, and cardiac re-
vascularizations. Stroke was deﬁned as a neurological
deﬁcit that lasted >24 h. Computed tomographic or
magnetic resonance imaging of the brain was recom-
mended and available in all but 16 cases (7,14). “All
cerebrovascular events,” in addition to stroke,
included transient ischemic attack and prolonged
ischemic neurological deﬁcit.
LABORATORY PROCEDURES. Blood samples were
taken before the start of dialysis and administration
of heparin or further drugs and before randomization.
Cholesterol was measured with enzymatic reagents
(Wako Chemicals GmbH, Neuss, Germany) on a 30R
analyzer (Wako Diagnostics, Richmond, Virginia) or
AU640 analyzer (Olympus Corporation, Tokyo,
Japan). Cholestanol was measured with gas chroma-
tography and mass spectrometry using the signiﬁcant
ion m/z 445.4. The details of the method have pre-
viously been described (15).
STATISTICAL ANALYSES. The baseline characteris-
tics are reported as counts (percentages) for categorical
data and as means  SD for continuous data according
to the atorvastatin and the placebo groups, within
tertiles of the cholestanol-to-cholesterol ratio. Differ-
ences in the distributions of baseline characteristics
between the atorvastatin and the placebo groups
within these tertiles were tested for with the chi-
square test for categorical data and Student t test
and analysis of variance for continuous data.
The effect of atorvastatin treatment on the risk
of reaching the endpoints in the entire cohort was
tested using time-to-event analyses (Cox regression
for endpoints with exclusively fatal events and
the Andersen-Gill model, which is an extended Cox
regression approach that allows for multiple events,
for endpoints that include nonfatal events) (16). The
analyses were adjusted for the following: sex; age;
phosphate; albumin; hemoglobin; glycated hemoglo-
bin; ever smoking; systolic and diastolic blood
pressures; body mass index; ultraﬁltration volume;
duration of dialysis; coronary artery disease (CAD)
(MI, coronary artery bypass grafting, coronary inter-
vention, and angiographically documented CAD);history of stroke/transient ischemic attack; peripheral
artery disease; congestive heart failure (predomi-
nantly presenting as New York Heart Association
functional class II); and arrhythmia. We then tested
whether the interaction term between the treatment
group and the cholestanol-to-cholesterol ratio tertiles
was signiﬁcantly associated with endpoints in the
entire cohort, again using time-to-event analyses (Cox
regression for endpoints with exclusively fatal events
and Andersen-Gill models for endpoints that included
nonfatal events) (16). The model included the previ-
ously mentioned covariates, the ratio tertiles, atorvas-
tatin treatment (main effect), and the interaction term
between the cholestanol-to-cholesterol ratio tertiles
and atorvastatin treatment. Goodness of ﬁt was tested
according to Grønnesby and Borgan (17). Next, stratiﬁed
analyses were performed to test the effect of atorvas-
tatin treatment on the risk of reaching endpoints
within the tertiles using the previously mentioned
adjustment, and omitting the tertiles and the interac-
tion term between the cholestanol-to-cholesterol ratio
tertiles and the atorvastatin treatment. All interaction
tests and subgroup analyses within the tertiles
were performed using both the intention-to-treat and
the per-protocol approach. In addition, Kaplan-Meier
curves were plotted and log-rank tests were per-
formed to test the effect of the atorvastatin treatment
within the tertiles of the cholestanol-to-cholesterol
ratio for the primary endpoint. All statistical tests
were 2-sided, and p values <0.05 were considered
signiﬁcant. Statistical analysis was conducted using
the STATA statistical software package (release 13;
StataCorp LP, College Station, Texas).
RESULTS
Summary statistics stratiﬁed by treatment group
within cholestanol-to-cholesterol ratio tertiles are
shown in Table 1. There were no signiﬁcant differ-
ences of any baseline characteristics across or within
the tertiles nor between treatment groups, except for
the prevalence of CAD in the second tertile and al-
bumin and arrhythmia in the third tertile. Potential
confounding caused by these nonbalanced variables
was controlled for by including them as covariates
in the time-to-event models.
Themean duration of follow-upwas 4.1 years. Only 1
patient was lost to follow-up, and this patient was
included in the analysis until loss to follow-up (7). The
patient was allocated to the placebo group in the ﬁrst
tertile. A total of 454 primary endpoints occurred. The
absolute numbers for all endpoints by treatment
groups within cholestanol-to-cholesterol ratio tertiles
are shown in Table 2. By performing multivariate
TABLE 1 Baseline Characteristics
Cholestanol-to-Cholesterol Ratio
p Value†
First Tertile Second Tertile Third Tertile
Threshold #0.77 mg/mg Threshold >0.77 to #1.50 mg/mg Threshold >1.50 mg/mg
Atorvastatin
(n ¼ 165)
Placebo
(n ¼ 178) p Value*
Atorvastatin
(n ¼ 177)
Placebo
(n ¼ 166) p Value*
Atorvastatin
(n ¼ 177)
Placebo
(n ¼ 167) p Value*
Cholestanol-to-cholesterol
ratio, mg/mg
0.40  0.21 0.38  0.21 0.446 1.13  0.21 1.12  0.21 0.869 4.16  7.46 3.34  5.15 0.236
Age, yrs 66.0  8.8 65.8  9.0 0.798 66.0  7.4 65.5  7.5 0.572 66.1  8.7 67.8  7.7 0.060 0.135
Male 88 (53.3) 96 (53.9) 0.911 92 (52.0) 89 (53.6) 0.762 97 (54.8) 84 (50.3) 0.403 0.959
BMI, kg/m2 27.4  4.1 27.6  5.3 0.786 27.7  4.5 27.2  4.6 0.267 27.4  5.2 27.4  5.4 0.953 0.966
Duration of dialysis,
months
17.1  8.0 18.4  8.1 0.126 18.0  8.8 19.4  8.8 0.154 17.5  8.7 18.4  87 0.318 0.278
Ultraﬁltration volume, l 2.1  1.3 2.4  1.3 0.063 2.4  1.1 2.3  1.1 0.564 2.2  1.2 2.2  1.3 0.894 0.387
Hemoglobin, g/dl 10.8  1.4 10.8  1.4 0.704 10.9  1.3 11.1  1.4 0.206 10.9  1.3 11.0  1.3 0.810 0.249
HbA1c, % 6.8  1.3 6.7  1.2 0.611 6.7  1.2 6.9  1.2 0.268 6.6  1.2 6.6  1.3 0.824 0.121
Fasting glucose, mg/dl 149  46 153  49 0.348 152  48 154  59 0.771 149  52 150  52 0.844 0.645
Systolic BP, mm Hg 145  23 145  19 0.918 147  23 145  24 0.414 146  21 146  23 0.982 0.852
Diastolic BP, mm Hg 76  11 76  11 0.731 75  11 75  10 0.694 76  11 76  12 0.692 0.258
Total cholesterol, mg/dl 217  42 218  40 0.861 221  45 218  42 0.510 219  45 223  42 0.422 0.478
LDL cholesterol, mg/dl 124  30 126  29 0.407 127  29 123  27 0.194 124  29 129  32 0.105 0.853
HDL cholesterol, mg/dl 34  12 36  13 0.189 36  13 37  14 0.580 37  13 38  13 0.743 0.088
Triglycerides, mg/dl 266  161 260  157 0.726 258  160 275  174 0.360 261  172 256  160 0.803 0.823
Phosphate, mg/dl 6.0  1.8 6.2  1.5 0.282 5.8  1.5 6.1  1.6 0.073 6.2  1.6 6.1  1.6 0.660 0.201
Albumin, g/dl 3.8  0.3 3.8  0.3 0.999 3.9  0.3 3.9  0.3 0.239 3.8  0.3 3.9  0.3 0.010 0.037
C-reactive protein, mg/l 11.8  22.9 11.9  19.1 0.979 11.1  24.8 12.0  21.7 0.711 11.8  14.4 9.8  10.3 0.130 0.766
Arrhythmia 34 (20.6) 33 (18.5) 0.630 34 (19.2) 23 (13.9) 0.183 30 (17.0) 43 (25.6) 0.046 0.300
CAD 49 (29.7) 63 (35.4) 0.261 59 (33.3) 37 (22.3) 0.023 49 (27.7) 50 (29.9) 0.644 0.360
Congestive HF 61 (37.0) 64 (36.0) 0.845 73 (41.2) 55 (33.1) 0.121 55 (31.1) 67 (40.1) 0.080 0.880
Peripheral artery disease 74 (44.9) 87 (48.9) 0.455 91 (51.4) 73 (44.0) 0.168 80 (45.2) 75 (44.9) 0.957 0.761
Stroke/TIA 23 (13.9) 35 (19.7) 0.158 38 (21.5) 33 (19.9) 0.717 30 (17.0) 27 (16.2) 0.846 0.295
Smoking 0.493 0.053 0.690 0.289
Never 97 (58.8) 115 (64.6) 102 (57.6) 109 (65.7) 98 (55.4) 97 (58.1)
Past 57 (34.5) 51 (28.7) 63 (35.6) 40 (24.1) 57 (32.2) 54 (32.3)
Current 11 (6.7) 12 (6.7) 12 (6.7) 17 (10.2) 22 (12.4) 16 (9.6)
Values are mean  SD or n (%). *p Value for difference between atorvastatin and placebo calculated with chi-square test for categorical data and Student t test for continuous data. †p Value for difference
across tertiles of cholestanol-to-cholesterol ratio calculated with chi-square test for categorical data and analysis of variance for continuous data.
BMI ¼ body mass index; BP ¼ blood pressure; CAD ¼ coronary artery disease; HbA1c ¼ glycosylated hemoglobin; HDL ¼ high-density lipoprotein; HF ¼ heart failure; LDL ¼ low-density lipoprotein;
TIA ¼ transient ischemic attack.
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2294analyses, the effect of atorvastatin treatment on the
risk of reaching the endpoints (Table 3) was consistent
with the results reported for all 1,255 participants (14).
By performing intention-to-treat analyses, the
interaction term between the tertiles and the treat-
ment group was signiﬁcantly associated with the risk
of reaching the primary endpoint (Table 4). The prob-
ability value of the Grønnesby and Borgan (17) test
conﬁrmed satisfactory goodness of ﬁt (Table 4). Sub-
group analyses within the cholestanol-to-cholesterol
ratio tertiles showed that atorvastatin reduced the
risk of reaching the primary endpoint in theﬁrst tertile,
but did not do so in the second and third tertiles
(Table 4, Central Illustration). These results were
conﬁrmed by per-protocol analyses (Online Table 1).
Consistent with the primary endpoint results,
atorvastatin treatment reduced the risk of death fromany cause, the risk of all cardiac events, and the
risk of cardiac death in the ﬁrst tertile, but not in
the second or third tertiles of the cholestanol-to-
cholesterol ratio on the basis of the intention-to-treat
analyses (Table 4). For sudden cardiac death, nonfatal
MI, and cerebrovascular endpoints, the number of
events was relatively small (Table 2). Nevertheless,
the effect of atorvastatin treatment appeared to be
least beneﬁcial in the third tertile of the cholestanol-
to-cholesterol ratio for each of these endpoints
(Table 4). These results were conﬁrmed by per-
protocol analyses (Online Table 1).
DISCUSSION
This post-hoc analysis of the 4D trial shows that pa-
tients on maintenance hemodialysis treatment with
TABLE 2 Events by Tertiles
Event Type
First Tertile Second Tertile Third Tertile
Atorvastatin
(n ¼ 165)
Placebo
(n ¼ 178)
Atorvastatin
(n ¼ 177)
Placebo
(n ¼ 166)
Atorvastatin
(n ¼ 177)
Placebo
(n ¼ 167)
Follow-up time, yrs 4.2 4.2 4.2 4.2 3.8 3.9
Primary endpoint First event 51 (30.9) 76 (42.7) 63 (35.6) 61 (36.7) 75 (42.4) 67 (40.1)
Second event 8 (4.8) 10 (5.6) 8 (4.5) 19 (11.4) 9 (5.1) 7 (4.2)
Total 59 86 71 80 84 74
Death from all causes Total 73 (44.2) 102 (57.3) 95 (53.7) 78 (47.0) 90 (50.8) 90 (53.9)
All cardiac events First event 46 (27.9) 80 (44.9) 60 (33.9) 60 (36.1) 63 (35.6) 66 (39.5)
Second event 16 (9.7) 23 (12.9) 8 (4.5) 24 (14.5) 18 (10.2) 17 (10.2)
Total 62 103 68 84 81 83
Cardiac death Total 26 (15.8) 48 (27.0) 39 (22.0) 32 (19.3) 39 (22.0) 42 (25.1)
Sudden cardiac death Total 17 (10.3) 25 (14.0) 29 (16.4) 18 22 (12.4) 21 (12.6)
Nonfatal MI First event 18 (10.9) 24 (13.5) 15 (8.5) 23 (13.9) 20 (11.3) 19 (11.4)
Second event 2 (1.2) 3 (1.7) 1 (0.6) 7 (4.2) 2 (1.1) 1 (0.6)
Total 20 27 16 30 22 20
All cerebrovascular events First event 16 (9.7) 18 (10.1) 21 (11.9) 21 (12.7) 28 (15.8) 21 (12.6)
Second event 1 (0.6) 2 (1.1) 4 (2.3) 3 (1.8) 7 (4.0) 6 (3.6)
Total 17 20 25 24 35 27
Stroke First event 12 (7.3) 11 (6.2) 14 (7.9) 16 (9.6) 23 (13.0) 10 (6.0)
Second event 1 (0.6) 0 (0.0) 2 (1.1) 2 (1.2) 0 (0.0) 2 (1.2)
Total 13 11 16 18 23 12
Values are n (%).
MI ¼ myocardial infarction.
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2295low cholesterol absorption rates may beneﬁt from
treatment with atorvastatin (Central Illustration). The
ﬁnding is of relevance, because hemodialysis patients
have an extremely high CV risk (18,19). Moreover,
therapeutic strategies to reduce this risk are scarce
or virtually absent (9). In particular, treatment with
statins has generally not been recommended in pa-
tients on maintenance hemodialysis treatment (20).TABLE 3 Risk of Endpoints*
HR (95% CI)† p Value†
Primary endpoint 0.87 (0.72–1.05) 0.145
Death from all causes 0.91 (0.77–1.08) 0.274
All cardiac events 0.77 (0.64–0.93) 0.006
Cardiac death 0.85 (0.66–1.10) 0.213
Sudden cardiac death 1.02 (0.74–1.42) 0.885
Nonfatal MI 0.74 (0.53–1.03) 0.074
All cerebrovascular events 1.06 (0.75–1.49) 0.758
Stroke 1.20 (0.77–1.89) 0.417
*Comparing the atorvastatin group versus placebo group (reference) in the
intention-to-treat cohort calculated with Andersen-Gill models or Cox regression.
†For difference between atorvastatin treatment and placebo in the entire cohort
adjusted for sex, age, phosphate, albumin, hemoglobin, HbA1c, ever smoking,
systolic and diastolic BP, BMI, ultraﬁltration volume, duration of dialysis, CAD (MI,
coronary artery bypass grafting, coronary intervention, and angiographically
documented CAD), history of stroke/TIA, peripheral artery disease, congestive HF
(predominantly presenting with New York Heart Association functional class II),
and arrhythmia.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Tables 1
and 2.These data agree with ﬁndings from the 4S (Scan-
dinavian Simvastatin Survival Study) trial (21),
beyond the obvious exception that statins appeared
to be more effective in reducing CV risk in the 4S than
in the 4D study (21). In the 4S study, simvastatin
treatment versus placebo signiﬁcantly reduced the
risk of major coronary events by 38% in the lowest
quartile of the cholestanol-to-cholesterol ratio, but
such treatment increased the risk of major coronary
events by 17% in the highest quartile (21). Both the
4S and 4D studies ﬁt well into our current under-
standing of cholesterol homeostasis (10): there is
some reason to think that treatment with statins,
which interfere with cholesterol synthesis, is less
effective in patients with advanced CKD who absorb
most of their cholesterol (11). In line with this idea,
the mean cholestanol-to-cholesterol ratio was higher
in the 4D study (1.8 mg/mg) than in the LURIC
(Ludwigshafen Risk and Cardiovascular Health)
study (1.5 mg/mg) (15), the Framingham Offspring
Study (1.4 mg/mg) (22), and especially the 4S study
(1.3 mg/mg) (21).
In contrast, inhibition of cholesterol absorption
may be instrumental to reduce CV risk in patients with
high cholesterol absorption (10). This pathophy-
siological background could be 1 of the reasons for the
results of the SHARP (Study of Heart And Renal Pro-
tection) (23). All participants in the SHARP study had
TABLE 4 Risk of Endpoints by Tertile*
First Tertile Second Tertile Third Tertile
p Value‡ p Value§ p ValuekHR (95% CI)† p Value† HR (95% CI)† p Value† HR (95% CI)† p Value†
Primary endpoint 0.72 (0.52–1.00) 0.049 0.79 (0.53–1.16) 0.225 1.21 (0.85–1.74) 0.287 0.702 0.042 0.140
Death from all causes 0.70 (0.52–0.96) 0.025 1.06 (0.76–1.47) 0.736 1.02 (0.73–1.43) 0.902 0.100 0.069 0.206
All cardiac events 0.65 (0.47–0.92) 0.014 0.73 (0.50–1.06) 0.097 1.07 (0.73–1.57) 0.736 0.684 0.070 0.369
Cardiac death 0.57 (0.33–0.98) 0.042 1.13 (0.67–1.90) 0.644 1.08 (0.70–1.66) 0.722 0.124 0.066 0.454
Sudden cardiac death 0.68 (0.33–1.39) 0.291 1.54 (0.82–2.90) 0.180 1.13 (0.63–2.06) 0.671 0.190 0.396 0.060
Nonfatal MI 0.81 (0.43–1.54) 0.520 0.51 (0.27–0.99) 0.040 1.10 (0.60–1.99) 0.766 0.335 0.406 0.886
All cerebrovascular events 0.92 (0.47–1.78) 0.800 0.93 (0.52–1.68) 0.814 1.28 (0.74–2.21) 0.372 0.865 0.401 0.095
Stroke 1.26 (0.60–2.67) 0.537 0.73 (0.33–1.62) 0.433 2.10 (1.02–4.33) 0.044 0.432 0.431 0.561
*Calculated with Andersen-Gill models or Cox regression. †For difference between atorvastatin treatment and placebo within the tertiles of the cholestanol-to-cholesterol ratio
adjusted for sex, age, phosphate, albumin, hemoglobin, HbA1c, ever smoking, systolic and diastolic BP, BMI, ultraﬁltration volume, duration of dialysis, history of stroke/TIA,
CAD (MI, coronary artery bypass graft [CABG], coronary intervention, and angiographically documented CAD), peripheral artery disease, congestive HF (predominantly pre-
senting with New York Heart Association [NYHA] functional class II), and arrhythmia. ‡For association of interaction term between tertiles and treatment group with endpoints
(second tertile vs. ﬁrst tertile) in the entire cohort. §For association of interaction term between tertiles and treatment group with endpoints (third tertile vs. ﬁrst tertile) in the
entire cohort. ‡ and § models included sex, age, phosphate, albumin, hemoglobin, HbA1c, ever smoking, systolic and diastolic BP, BMI, ultraﬁltration volume, duration of
dialysis, history of stroke/TIA, CAD (MI, CABG, coronary intervention, and angiographically documented CAD), peripheral artery disease, congestive HF (predominantly pre-
senting with NYHA functional class II), arrhythmia, tertiles, atorvastatin treatment (main effect), and the interaction term between the tertiles and atorvastatin treatment.
kFor goodness of ﬁt calculated according to Grønnesby and Borgan (17) in the entire cohort.
Abbreviations as in Tables 1 to 3.
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2296CKD, and 33% of the cohort received maintenance
hemodialysis treatment. A total of 9,270 participants
were randomized to either simvastatin plus ezetimibe,
a cholesterol absorption inhibitor, or placebo. The
combination therapy of simvastatin and ezetimibe
signiﬁcantly reduced the risk of major atherosclerotic
events by 17%. The present data lend support for
the strategy to inhibit both cholesterol synthesis and
cholesterol absorption, especially in hemodialysis
patients. Moreover, the present post-hoc analysis of
the 4D trial suggests that measurement of cholesterol
absorption may help to identify hemodialysis patients
who would beneﬁt from treatment with statins. This
would be an approach to personalized medicine,
which seems of particular relevance in high CV risk
hemodialysis patients on polypharmacy therapy (24).
However chromatography– and mass spectrometry–
based measurement of cholestanol is still cost-
demanding, time-consuming, and only offered by
specialized laboratories. Moreover, standardizing the
methods to measure cholestanol has not yet
concluded, and an international standardization
effort is still ongoing (25).
This work has major strengths. First, we report on
data from the 4D study that represents 1 of only 2
randomized controlled trials that investigated the
effectiveness of statin treatment to reduce CV risk only
in patients who received maintenance hemodialysis
treatment. The cohort is large and well characterized,
and there was a comprehensive follow-up with a
considerable amount of fatal and nonfatal events
yielding high statistical power (7,14). Second, the pre-
sent study is the ﬁrst to investigate the impact of
cholesterol absorption on the effectiveness of statintreatment to prevent CV complications in patients on
maintenance hemodialysis treatment. Third, we used
the cholestanol-to-cholesterol ratio as a measure of
cholesterol absorption. This estimate is less prone to
confounding by diet than other biomarkers for
cholesterol absorption efﬁciency (12,13). Fourth, the
laboratory personnel responsible for measuring cho-
lestanol were blinded to all of the clinical and
biochemical data of the participants. Fifth, confound-
ing due to the use of drugs that interfere with choles-
terol metabolism is unlikely. Cholestyramine, a bile
acid sequestrant, was not used by any patient, because
in Germany this medicine is regarded as contra-
indicated for hemodialysis patients because of it in-
creases triglycerides. Sevelamer, a phosphate-binding
drug with a structure similar to bile acid resins, was
approved in Germany, but not until early 2000, and
was taken by <1% of the study participants due to its
slow introduction on themarket (recruitment between
March 1998 and October 2002). Ezetimibe and ﬁbrates
were not taken by any patient. Sixth, the results ob-
tained from intention-to-treat analyses were
conﬁrmed by per-protocol analyses.
STUDY LIMITATIONS. The observational character of
the present study might be a limitation because the
study was a post-hoc analysis. However, we had a
clear hypothesis that was conﬁrmed following a
pre-deﬁned statistical analysis plan. In addition, di-
etary intake of cholesterol or saturated fat was not
recorded by survey or questionnaire. Finally, single
nucleotide polymorphisms in the ABCG8 (e.g.,
rs4245791, rs4299376, rs41360247, rs6576629, and
rs4953023) and ABO (e.g., rs657152) genes, which
CENTRAL ILLUSTRATION Risk of Reaching the Primary Endpoint in Participants of the 4D Study on the Basis of
Intestinal Cholesterol Absorption
Silbernagel, G. et al. J Am Coll Cardiol. 2015; 65(21):2291–8.
In a post-hoc analysis of hemodialysis patients participating in the German Diabetes and Dialysis Study randomized to atorvastatin or placebo group, and stratiﬁed by
tertiles of the cholestanol-to-cholesterol ratio, statin effectiveness was dependent on intestinal cholesterol absorption. Those in the ﬁrst tertile (A) experienced a
reduction in the risk of reaching the primary endpoint, a composite of major cardiovascular events; patients in the second (B) and third (C) tertiles had no similar
risk reduction.
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2297have been implicated in cholesterol absorption and
low-density lipoprotein cholesterol concentrations
(13), were not analyzed in the 4D study. These single
nucleotide polymorphisms might help to predict the
effectiveness of statin treatment to reduce CV risk.
A large meta-analysis that includes several statin
intervention trials testing for such a relationship is
therefore encouraged.
Cholesterol absorption is regulated in a com-
plex fashion (10). In hemodialysis, speciﬁc metabolicalterations probably play a more dominant role
in the regulation of cholesterol absorption than
genetic variations. However, the prevalence of
common low-density lipoprotein cholesterol-raising
variants in the ABCG8 and ABO genes may
be slightly higher in hemodialysis patients with
a high cholestanol-to-cholesterol ratio. Moreover,
it will be of interest to test whether the expres-
sion of these genes is inﬂuenced by the uremic
state.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
efﬁcacy of atorvastatin to reduce cardiovascular risk in
patients who are receiving hemodialysis is inversely
related to cholesterol absorption.
TRANSLATIONAL OUTLOOK: Future studies
should investigate the safety and efﬁcacy of inter-
ventions that inhibit cholesterol absorption in patients
on hemodialysis with high rates of cholesterol
absorption.
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2298CONCLUSIONS
We found that measurement of cholesterol absorption
may help to identify hemodialysis patients who will
beneﬁt from treatment with statins. Beyond that, the
data might argue in favor of a combination therapy
that addresses both cholesterol synthesis and ab-
sorption to reduce CV risk in hemodialysis patients.
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